Analyst Suggests MannKind Could Receive FDA Approval for Afrezza If Trials Pass
June 21, 2013 at 10:59 AM EDT
About one hour after the open MannKind (NASDAQ: MNKD ) shares are trading down about 4 percent despite some bullish views from an analyst at Summer Street. The analyst believes MannKind's new drug Afrezza is ready for approval by the FDA -- with one catch: the drug needs to pass
